Polar Asset Management Partners Inc. Acquires Shares of 229,806 COMPASS Pathways PLC Sponsored ADR $CMPS

Key Points

• Polar Asset Management Partners Inc. acquired 229,806 shares of COMPASS Pathways PLC, valued at approximately $657,000, increasing its stake to around 0.25% of the company.
• Multiple institutional investors, including RTW Investments and Nantahala Capital Management, have recently increased their holdings in COMPASS, with Nantahala boosting its stake by 182.9%.
• COMPASS Pathways reported a quarterly earnings miss with ($0.38) earnings per share, while analysts have set varying price targets, with a consensus target of $16.29.

Polar Asset Management Partners Inc. purchased a new stake in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 229,806 shares of the company's stock, valued at approximately $657,000. Polar Asset Management Partners Inc. owned 0.25% of COMPASS Pathways as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Jane Street Group LLC lifted its position in shares of COMPASS Pathways by 72.7% during the 4th quarter. Jane Street Group LLC now owns 51,815 shares of the company's stock worth $196,000 after purchasing an additional 21,815 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of COMPASS Pathways by 93.6% during the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock worth $30,000 after purchasing an additional 5,003 shares during the last quarter. Tang Capital Management LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter worth $3,780,000. ARK Investment Management LLC lifted its position in shares of COMPASS Pathways by 4.0% during the 1st quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company's stock worth $5,162,000 after purchasing an additional 68,601 shares during the last quarter. Finally, 22NW LP purchased a new stake in shares of COMPASS Pathways during the 1st quarter worth $1,849,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Performance

NASDAQ CMPS traded down $0.04 during trading on Friday, reaching $5.21. The company's stock had a trading volume of 318,778 shares, compared to its average volume of 1,816,599. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.82 and a current ratio of 8.82. The firm has a market cap of $499.37 million, a price-to-earnings ratio of -2.83 and a beta of 2.17. COMPASS Pathways PLC Sponsored ADR has a twelve month low of $2.25 and a twelve month high of $7.53. The business's fifty day moving average price is $4.33 and its 200-day moving average price is $3.89.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). As a group, analysts anticipate that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. HC Wainwright decreased their price objective on shares of COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, August 4th. Evercore ISI reissued an "in-line" rating and issued a $6.00 price target (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Canaccord Genuity Group reissued a "buy" rating and issued a $15.00 price target on shares of COMPASS Pathways in a research report on Friday, August 1st. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $12.00 price target on shares of COMPASS Pathways in a research report on Tuesday, May 27th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, COMPASS Pathways currently has an average rating of "Moderate Buy" and an average target price of $16.29.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.